<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

TCL Archive

Risk of Lymphoma Increases with Hepatitis C Virus Infection

Long-Term Results Find Cisplatin Improves Survival

Study Links Ovarian Cancer To Hormone Replacement

Smokers Who Quit Live Longer Than Those Who Spit-Study

FDA Approves New Drug for Advanced Kidney Cancer

FDA Approves New Indication For Anticoagulant Frangmin

NCI-Approved Group, Center Clinical Trials Listed

After ODAC: Questions On ESA Claims, Advertising, Reimbursement Gain Urgency.

Amgen Claimed QOL Benefit Despite FDA Label Change.

“Miracle-Gro for Cancer?” ODAC Members Vent At Amgen And J&J Over Claims, Advertising.